Harirai Pharmaceuticals (Opc) Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 7 Year,
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.00 M
- Revenue Growth 1252.01%
- Profit Growth 17854.39%
- Ebitda -10776.12%
- Net Worth 16.53%
- Total Assets 301.55%
About Harirai Pharmaceuticals (Opc)
Harirai Pharmaceuticals (Opc) Private Limited (HPOPL) is a registered startup operating as a Company incorporated in India on 24 February 2018 (Seven years 0 days old ). Its registered office is in Khorda, Odisha, India.
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹1.00 M.
Debashis Samal serves as a director at the Company.
Company Details
- Location
Khorda, Odisha, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U93090OR2018OPC028390
- Company No.
028390
- Incorporation Date
24 Feb 2018
- Date of AGM
-
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Cuttack
Industry
Who are the key members and board of directors at Harirai Pharmaceuticals (Opc)?
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Debashis Samal  | Director | 24-Feb-2018 | Current |
Financial Performance of Harirai Pharmaceuticals (Opc).
Harirai Pharmaceuticals (Opc) Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 1252.01% increase. The company also saw a substantial improvement in profitability, with a 17854.39% increase in profit. The company's net worth Soared by an impressive increase of 16.53%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Harirai Pharmaceuticals (Opc)?
In 2019, Harirai Pharmaceuticals (Opc) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Infusupport Private LimitedDebashis Samal is a mutual person
Charges (Loans)
₹1.00 M
₹0
Charges Breakdown by Lending Institutions
- Bank Of India : 0.10 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 08 Aug 2019 | Bank Of India | ₹1.00 M | Open |
How Many Employees Work at Harirai Pharmaceuticals (Opc)?
Unlock and access historical data on people associated with Harirai Pharmaceuticals (Opc), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Harirai Pharmaceuticals (Opc), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Harirai Pharmaceuticals (Opc)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.